RU2004131636A - Способ лечения ожирения - Google Patents
Способ лечения ожирения Download PDFInfo
- Publication number
- RU2004131636A RU2004131636A RU2004131636/14A RU2004131636A RU2004131636A RU 2004131636 A RU2004131636 A RU 2004131636A RU 2004131636/14 A RU2004131636/14 A RU 2004131636/14A RU 2004131636 A RU2004131636 A RU 2004131636A RU 2004131636 A RU2004131636 A RU 2004131636A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- enhances
- norepinephrine
- dopamine
- activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Claims (17)
1. Способ лечения ожирения у млекопитающих, содержащий введение нуждающемуся в таком лечении млекопитающему по меньшей мере одного способствующего потере веса противосудорожного средства и по меньшей мере одного состава, который усиливает активность норэпинефрина и/или дофамина, в таких количествах, чтобы упомянутое лечение было эффективно.
2. Способ по п.1, в котором упомянутое противосудорожное средство имеет формулу (I):
где Х представляет собой СН2 или кислород,
R1 является водородом или алкилом,
R2, R3, R4 и R5 представляют собой независимо водород или более низкий алкил, а когда Х является СН2, R4 и R5 могут быть алкеновыми группами, соединенными для образования бензольного кольца, и когда Х является кислородом, R2 и R3 и/или R4 и R5 вместе могут быть метиленэди-окси-группой следующей формулы (II):
где R6 и R7 являются одинаковыми или разными и представляют собой водород, более низкий алкил или являются алкилом и соединяются для образования циклопентального или циклогексильного кольца.
3. Способ по п.2, в котором R1 является водородом или C1-C4 алкильной прямой или разветвленной цепью, и R2, R3, R4, R5, R6 и R7 являются C1-С3 алкильной прямой или разветвленной цепью.
4. Способ по п.1, в котором упомянутое противосудорожное средство имеет формулу (III):
где R1 является водородным или галогенным атомом, R2 и R3 являются одинаковыми или разными и представляют собой каждый водород или алкил, имеющий 1-3 атома углерода, а один из Х и Y является атомом углерода, а другой является атомом азота при условии, что -CH2SO2NR2R3 связана с атомом углерода либо X, либо Y, или их щелочно-металлической соли.
5. Способ по п.1, в котором упомянутое противосудорожное средство представляет собой зонизамид или топирамат.
6. Способ по п.1, в котором упомянутый состав, который усиливает активность норэпинефрина и/или дофамина, осуществляет усиление через подавление усвоения.
7. Способ по п.1, в котором упомянутый состав, который усиливает активность норэпинефрина и/или дофамина, представляет собой бупропион, атомоксетин или рибоксетин.
8. Способ по п.1, в котором упомянутое противосудорожное средство и упомянутый состав, который усиливает активность норэпинефрина и/или дофамина, вводятся по отдельности.
9. Способ по п.1, в котором упомянутое противосудорожное средство и упомянутый состав, который усиливает активность норэпинефрина и/или дофамина, вводятся одновременно.
10. Способ снижения риска гипертонии, диабетов или дислипидемии у млекопитающего, содержащий введение нуждающемуся в таком снижении млекопитающему по меньшей мере одного способствующего потере веса противосудорожного средства и по меньшей мере одного состава, который усиливает активность норэпинефрина и/или дофамина в таких количествах, чтобы осуществлялось упомянутое снижение.
11. Способ лечения ожирения у млекопитающих, содержащий введение нуждающемуся в таком лечении млекопитающему состава с формулой (III):
где R1 является водородным или галогенным атомом, R2 и R3 являются одинаковыми или разными и представляют собой каждый водород или алкил, имеющий 1-3 атома углерода, а один из Х и Y является атомом углерода, а другой является атомом азота при условии, что -CH2SO2NR2R3 связана с атомом углерода либо X, либо Y, или их щелочно-металлической соли, в количествах, достаточных для осуществления упомянутого лечения.
12. Способ по п.11, в котором упомянутый состав представляет собой зонизамид.
13. Композиция, содержащая по меньшей мере одно способствующее потере веса противосудорожное средство и по меньшей мере один состав, который усиливает активность норэпинефрина и/или дофамина.
14. Композиция по п.13, в которой упомянутый состав находится в виде единицы дозировки.
15. Композиция по п.14, в которой упомянутый состав находится в виде таблетки или капсулы.
16. Композиция по п.13, в которой упомянутое средство представляет собой зонизамид или топирамат.
17. Композиция по п.13, в которой упомянутый состав, который усиливает активность норэпинефрина и/или дофамина, представляет собой бупропион.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38087402P | 2002-05-17 | 2002-05-17 | |
US60/380,874 | 2002-05-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2004131636A true RU2004131636A (ru) | 2005-06-27 |
RU2341259C2 RU2341259C2 (ru) | 2008-12-20 |
Family
ID=29550030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2004131636/14A RU2341259C2 (ru) | 2002-05-17 | 2003-05-19 | Способ лечения ожирения |
Country Status (11)
Country | Link |
---|---|
US (7) | US7109198B2 (ru) |
EP (3) | EP2301537A1 (ru) |
JP (1) | JP4545584B2 (ru) |
KR (2) | KR101072885B1 (ru) |
CN (1) | CN1320886C (ru) |
AU (1) | AU2003231788B2 (ru) |
CA (1) | CA2483464C (ru) |
HK (1) | HK1074778A1 (ru) |
MX (1) | MXPA04011203A (ru) |
RU (1) | RU2341259C2 (ru) |
WO (1) | WO2003097046A1 (ru) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
US20040029941A1 (en) * | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
US20190290618A1 (en) * | 2002-05-17 | 2019-09-26 | Duke University | Method for Treating Obesity |
KR101072885B1 (ko) * | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
US20050215552A1 (en) * | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
US20190262318A1 (en) * | 2002-05-17 | 2019-08-29 | Duke University | Method for Treating Obesity |
US20050059718A1 (en) * | 2003-02-21 | 2005-03-17 | Hayato Miyachi | Methods of using zonisamide as an adjunctive therapy for partial seizures |
MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
US20050043773A1 (en) * | 2003-08-21 | 2005-02-24 | Ivan Lieberburg | Methods of improving the safety of zonisamide therapy |
US20050043704A1 (en) * | 2003-08-21 | 2005-02-24 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154033A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154032A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154034A1 (en) * | 2004-01-08 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154037A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20050154036A1 (en) * | 2004-01-09 | 2005-07-14 | Eisai Co., Ltd. | Methods of using zonisamide as an adjunctive therapy for partial seizures |
US20060160750A1 (en) * | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
KR20060128995A (ko) | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
SE0400378D0 (sv) * | 2004-02-17 | 2004-02-17 | Jan Hedner | Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet |
WO2005107806A1 (en) * | 2004-04-21 | 2005-11-17 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
CN1968692A (zh) * | 2004-05-03 | 2007-05-23 | 杜克大学 | 影响体重减轻的组合物 |
US20060153934A1 (en) * | 2005-01-13 | 2006-07-13 | Navitas Pharma | Combination therapies of cicletanine and magnesium |
US20060276412A1 (en) * | 2005-05-31 | 2006-12-07 | Gary Tollefson | Methods and compositions for managing psychotic disorders |
JP5095615B2 (ja) * | 2005-06-27 | 2012-12-12 | バリアント・インターナショナル・(バルバドス)・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ | ブプロピオン塩の放出調整製剤 |
WO2007022344A2 (en) | 2005-08-17 | 2007-02-22 | Hill's Pet Nutrition, Inc. | Methods and compositions for the preventioin and treatment of kidney disease |
US20070077310A1 (en) * | 2005-10-03 | 2007-04-05 | University Of Tennessee Research Foundation | Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species |
WO2007047351A2 (en) * | 2005-10-13 | 2007-04-26 | Orexigen Therapeutics, Inc. | Methods for treating hypertension in overweight and obese individuals |
ES2761812T3 (es) * | 2005-11-22 | 2020-05-21 | Nalpropion Pharmaceuticals Inc | Composición y métodos de aumento de la sensibilidad a la insulina |
WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
TWI425944B (zh) * | 2005-11-28 | 2014-02-11 | Orexigen Therapeutics Inc | 唑尼沙胺(zonisamide)之持續釋放調配物 |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
US8088786B2 (en) * | 2006-11-09 | 2012-01-03 | Orexigen Therapeutics, Inc. | Layered pharmaceutical formulations |
JP2011521973A (ja) * | 2008-05-30 | 2011-07-28 | オレキシジェン・セラピューティクス・インコーポレーテッド | 内臓脂肪の状態を処置するための方法 |
US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
WO2009152152A1 (en) * | 2008-06-09 | 2009-12-17 | Amarillo Biosciences, Inc. | Treatment of obesity with an interferon |
US8114445B2 (en) * | 2008-11-07 | 2012-02-14 | Reliv International Inc. | Dietary supplement for promoting wellness and weight loss and methods of administering the same |
CN104222518A (zh) * | 2008-12-30 | 2014-12-24 | 希尔氏宠物营养品公司 | 用于治疗和预防伴侣动物的与体重相关疾病的组合物和方法 |
EP2515656B1 (en) * | 2009-12-21 | 2014-08-06 | Merck Sharp & Dohme Corp. | Aminobenzoquinazolinone m1 receptor positive allosteric modulators |
JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
WO2011163231A2 (en) | 2010-06-21 | 2011-12-29 | Theracos, Inc. | Combination therapy for the treatment of diabetes |
US10576045B2 (en) | 2011-02-16 | 2020-03-03 | Nir Barak | Low dosage combinations of fluoxetine and reboxetine for treating obesity |
MX2014000419A (es) | 2011-07-15 | 2014-09-22 | Nusirt Sciences Inc | Composicones y metodos para modular trayectorias metabolicas. |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
ES2924024T3 (es) | 2012-06-06 | 2022-10-04 | Nalpropion Pharmaceuticals Llc | Composición para su uso en un método para el tratamiento del sobrepeso y la obesidad en pacientes con alto riesgo cardiovascular |
CN108295058A (zh) | 2012-11-13 | 2018-07-20 | 纽斯尔特科学公司 | 用于增强能量代谢的组合物和方法 |
EP2945616B1 (en) | 2013-01-15 | 2018-11-28 | NuSirt Sciences, Inc. | Treating pulmonary conditions |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
CN105228627B (zh) | 2013-03-15 | 2018-07-13 | 纽斯尔特科学公司 | 亮氨酸和烟酸降低脂质水平 |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
SG11201607075TA (en) | 2014-02-27 | 2016-09-29 | Nusirt Sciences Inc | Compositions and methods for the reduction or prevention of hepatic steatosis |
US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
WO2019038584A1 (en) | 2017-08-19 | 2019-02-28 | Ftf Pharma Private Limited | ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PREPARATION METHOD THEREOF |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US122033A (en) * | 1871-12-19 | Improvement in rotary engines | ||
US100205A (en) * | 1870-02-22 | Improvement in furnaces | ||
US144174A (en) * | 1873-10-28 | Improvement in steam-engine valve-gears | ||
US254208A (en) * | 1882-02-28 | Geoegb e | ||
US277579A (en) * | 1883-05-15 | Axle-skein | ||
US181070A (en) * | 1876-08-15 | Improvement in burglar-proof gratings | ||
US33965A (en) * | 1861-12-17 | Improvement in rifle-sights | ||
US9514A (en) * | 1853-01-04 | Improvement in self-winding telegraphic registers | ||
US58293A (en) * | 1866-09-25 | Improved lady s-saddle tree | ||
US79501A (en) * | 1868-06-30 | Jambs righey | ||
US2462A (en) * | 1842-02-21 | Worked buttons on the heads | ||
US160750A (en) * | 1875-03-16 | Improvement in grain-separators | ||
US55008A (en) * | 1866-05-22 | Improved clothes-sprinkler | ||
US154002A (en) * | 1874-08-11 | Improvement in electric telegraphs | ||
US106576A (en) * | 1870-08-23 | Improvement in washing-machines | ||
US137144A (en) * | 1873-03-25 | Improvement in stop-cocks | ||
US142290A (en) * | 1873-08-26 | Improvement in trimming attachments for sewing-machines | ||
US215552A (en) * | 1879-05-20 | Improvement in gar-couplings | ||
US143322A (en) * | 1873-09-30 | blake | ||
US26986A (en) * | 1860-01-31 | Mortising-machine | ||
BE759838A (fr) | 1969-12-04 | 1971-06-03 | Wellcome Found | Cetones a activite biologique |
US3885046A (en) | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
US4089855A (en) * | 1976-04-23 | 1978-05-16 | Cornell Research Foundation, Inc. | Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby |
US4172896A (en) * | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
US4689332A (en) * | 1984-04-09 | 1987-08-25 | Research Corporation | Growth regulation and related applications of opioid antagonists |
US5266574A (en) * | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
US4673679A (en) * | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
NL8800823A (nl) * | 1987-04-10 | 1988-11-01 | Sandoz Ag | Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten. |
US5719197A (en) * | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
AU5439890A (en) | 1989-05-09 | 1990-11-29 | Whitby Research, Inc. | A method of reducing body weight and food intake using a dopamine d2 receptor agonist |
FR2657350B1 (fr) | 1990-01-19 | 1992-05-15 | Centre Nat Rech Scient | Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone. |
US5486362A (en) * | 1991-05-07 | 1996-01-23 | Dynagen, Inc. | Controlled, sustained release delivery system for treating drug dependency |
US5403595A (en) * | 1991-05-07 | 1995-04-04 | Dynagen, Inc. | Controlled, sustained release delivery system for smoking cessation |
GB9217295D0 (en) * | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5312925A (en) * | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
US5541231A (en) * | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
US5358970A (en) * | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
GB9315856D0 (en) * | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
CA2197554A1 (en) | 1994-09-19 | 1996-03-28 | The Du Pont Merck Pharmaceutical Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US5713488A (en) * | 1996-01-24 | 1998-02-03 | Farrugia; John V. | Condom dispenser |
EP0828489A4 (en) * | 1996-03-13 | 2001-04-04 | Univ Yale | Smoking cessation treatment using naltrexone and related compounds |
US20040024006A1 (en) | 1996-05-06 | 2004-02-05 | Simon David Lew | Opioid pharmaceutical compositions |
DK0915697T3 (da) | 1996-06-28 | 2003-01-27 | Ortho Mcneil Pharm Inc | Antikonvulsive sulfamatderivater, som er anvendelige ved behandling af fedme |
FR2758723B1 (fr) | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
JP2001518520A (ja) * | 1997-10-03 | 2001-10-16 | キャリー メディカル コーポレイション | ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物 |
US6262049B1 (en) * | 1997-10-28 | 2001-07-17 | Schering Corporation | Method of reducing nicotine and tobacco craving in mammals |
IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
KR100508393B1 (ko) * | 1997-12-26 | 2005-08-17 | 다이닛본 세이야꾸 가부시끼가이샤 | 신경변성질환 치료약 |
BR9907203A (pt) * | 1998-01-21 | 2000-10-17 | Glaxo Group Ltd | "composto, composições farmacêuticas, uso de um composto, e, processo de tratametno de depressão, distúrbio de hiperatividade por deficiência de atenção (adhd), obesidade, enxaqueca, dor, disfunção sexual, doença de parkinson, doença de alzeheimer, ou vìcio de cocaìna ou de produtos contendo nicotina (especialmente tabaco) em um indivìduo animal ou humano. " |
WO1999038504A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (-)-bupropion |
US6048322A (en) * | 1998-04-15 | 2000-04-11 | Kushida; Clete | Morphometric measurement tool |
US6150366A (en) * | 1998-06-15 | 2000-11-21 | Pfizer Inc. | Ziprasidone formulations |
US20030144174A1 (en) | 1998-12-09 | 2003-07-31 | Miles B. Brennan | Methods for identifying compounds useful for the regulation of body weight and associated conditions |
WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US8545880B2 (en) * | 1999-02-26 | 2013-10-01 | Andrx Pharmaceuticals, Llc | Controlled release oral dosage form |
US6210716B1 (en) * | 1999-02-26 | 2001-04-03 | Andrx Pharmaceuticals, Inc. | Controlled release bupropion formulation |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
US6342496B1 (en) | 1999-03-01 | 2002-01-29 | Sepracor Inc. | Bupropion metabolites and methods of use |
US6267995B1 (en) | 1999-03-03 | 2001-07-31 | Pure World Botanicals, Inc. | Extract of Lepidium meyenii roots for pharmaceutical applications |
EP1204626B1 (en) | 1999-04-01 | 2008-01-16 | Esperion Therapeutics Inc. | Ether compounds, compositions, and uses thereof |
PL350924A1 (en) | 1999-04-06 | 2003-02-10 | Sepracor Inc | Derivatives of venlafaxine and methods of preparing and using the same |
US6420369B1 (en) | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US7056890B2 (en) | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
EP1187603B1 (en) | 1999-06-14 | 2007-08-08 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
DE60020613T2 (de) * | 1999-07-01 | 2006-03-16 | Pharmacia & Upjohn Co. Llc, Kalamazoo | (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen |
US6071918A (en) * | 1999-07-21 | 2000-06-06 | Dupont Pharmaceuticals Company | Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence |
US6403657B1 (en) | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
WO2001026641A2 (en) * | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
US20030144271A1 (en) * | 2000-01-22 | 2003-07-31 | Albert Shulman | Methods for the treatment of substance abuse |
US20020090615A1 (en) * | 2000-01-31 | 2002-07-11 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
ATE326222T1 (de) * | 2000-03-15 | 2006-06-15 | Wolfgang Sadee | Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch |
US6437147B1 (en) * | 2000-03-17 | 2002-08-20 | Novo Nordisk | Imidazole compounds |
US6191117B1 (en) | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
US6627653B2 (en) * | 2000-08-02 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
DE60134251D1 (de) * | 2000-09-18 | 2008-07-10 | Sanos Bioscience As | Verwendung von glp-2-peptiden |
EP1333887B1 (en) * | 2000-10-30 | 2006-08-02 | Ortho-McNeil Pharmaceutical, Inc. | Combination therapy comprising anti-diabetic and anticonvulsant agents |
US6569449B1 (en) * | 2000-11-13 | 2003-05-27 | University Of Kentucky Research Foundation | Transdermal delivery of opioid antagonist prodrugs |
US20030087896A1 (en) | 2001-08-09 | 2003-05-08 | Hillel Glover | Treatment of refractory depression with an opiate antagonist and an antidepressant |
US6481031B1 (en) * | 2001-11-14 | 2002-11-19 | In Mo Hwang | Pillow oriented for comfort in varying sleeping positions |
US20040029941A1 (en) | 2002-05-06 | 2004-02-12 | Jennings Julianne E. | Zonisamide use in obesity and eating disorders |
US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
KR101072885B1 (ko) | 2002-05-17 | 2011-10-17 | 듀크 유니버시티 | 비만치료방법 |
EP1534074A4 (en) | 2002-07-18 | 2008-01-09 | Merck & Co Inc | POLYTHERAPY FOR THE TREATMENT OF OBESITY |
JP2006507251A (ja) | 2002-09-13 | 2006-03-02 | エーザイ株式会社 | 振せんの治療方法 |
US20040122033A1 (en) | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
MXPA05011557A (es) | 2003-04-29 | 2006-03-09 | Orexigen Therapeutics Inc | Composiciones para afectar perdida de peso. |
EP1635813A4 (en) | 2003-06-06 | 2009-07-01 | Merck & Co Inc | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA |
WO2004110375A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes |
WO2004110368A2 (en) | 2003-06-06 | 2004-12-23 | Merck & Co., Inc. | Combination therapy for the treatment of hypertension |
US7759358B2 (en) | 2003-07-23 | 2010-07-20 | Crooks Peter A | Oral bioavailable prodrugs |
KR100965580B1 (ko) * | 2003-08-21 | 2010-06-23 | 엘지디스플레이 주식회사 | 액정표시장치와 그의 구동방법 |
WO2005049043A1 (en) | 2003-11-18 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | Combination therapy comprising metformin and anticonvulsant agents |
KR20060128995A (ko) | 2004-01-13 | 2006-12-14 | 듀크 유니버시티 | 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물 |
US7713959B2 (en) | 2004-01-13 | 2010-05-11 | Duke University | Compositions of an anticonvulsant and mirtazapine to prevent weight gain |
US20060160750A1 (en) | 2004-01-13 | 2006-07-20 | Krishnan K R R | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss |
WO2005107806A1 (en) | 2004-04-21 | 2005-11-17 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
CN1968692A (zh) | 2004-05-03 | 2007-05-23 | 杜克大学 | 影响体重减轻的组合物 |
EP1773308A1 (en) | 2004-08-03 | 2007-04-18 | Orexigen Therapeutics, Inc. | Combination of bupropion and a second compound for affecting weight loss |
EP1827450A4 (en) * | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
US7346233B2 (en) * | 2005-02-14 | 2008-03-18 | Corning Incorporated | Single mode (SM) fiber optical reader system and method for interrogating resonant waveguide-grating sensor(s) |
-
2003
- 2003-05-19 KR KR1020047018476A patent/KR101072885B1/ko active IP Right Grant
- 2003-05-19 JP JP2004505045A patent/JP4545584B2/ja not_active Expired - Fee Related
- 2003-05-19 AU AU2003231788A patent/AU2003231788B2/en not_active Expired
- 2003-05-19 EP EP10185789A patent/EP2301537A1/en not_active Ceased
- 2003-05-19 EP EP03753096.1A patent/EP1505967B1/en not_active Expired - Lifetime
- 2003-05-19 US US10/440,404 patent/US7109198B2/en not_active Expired - Lifetime
- 2003-05-19 CN CNB038112299A patent/CN1320886C/zh not_active Expired - Lifetime
- 2003-05-19 KR KR1020117003379A patent/KR20110043664A/ko not_active Application Discontinuation
- 2003-05-19 RU RU2004131636/14A patent/RU2341259C2/ru active
- 2003-05-19 EP EP16178084.6A patent/EP3173082A1/en not_active Withdrawn
- 2003-05-19 CA CA2483464A patent/CA2483464C/en not_active Expired - Lifetime
- 2003-05-19 WO PCT/US2003/015703 patent/WO2003097046A1/en active Application Filing
- 2003-05-19 MX MXPA04011203A patent/MXPA04011203A/es active IP Right Grant
-
2004
- 2004-04-23 US US10/830,071 patent/US7425571B2/en not_active Expired - Lifetime
-
2005
- 2005-02-15 US US11/058,981 patent/US20050137144A1/en not_active Abandoned
- 2005-02-15 US US11/059,027 patent/US20050143322A1/en not_active Abandoned
- 2005-08-15 HK HK05107036.6A patent/HK1074778A1/zh not_active IP Right Cessation
- 2005-09-07 US US11/222,135 patent/US20060009514A1/en not_active Abandoned
-
2006
- 2006-05-05 US US11/381,990 patent/US20080188476A1/en not_active Abandoned
-
2008
- 2008-09-05 US US12/205,769 patent/US7754748B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20080319036A1 (en) | 2008-12-25 |
EP2301537A1 (en) | 2011-03-30 |
US7109198B2 (en) | 2006-09-19 |
KR101072885B1 (ko) | 2011-10-17 |
CA2483464C (en) | 2011-12-20 |
US20040198668A1 (en) | 2004-10-07 |
JP2005530782A (ja) | 2005-10-13 |
EP3173082A1 (en) | 2017-05-31 |
HK1074778A1 (zh) | 2005-11-25 |
MXPA04011203A (es) | 2005-07-14 |
EP1505967B1 (en) | 2016-07-13 |
AU2003231788A1 (en) | 2003-12-02 |
CN1320886C (zh) | 2007-06-13 |
US7425571B2 (en) | 2008-09-16 |
US7754748B2 (en) | 2010-07-13 |
EP1505967A1 (en) | 2005-02-16 |
KR20110043664A (ko) | 2011-04-27 |
KR20050023265A (ko) | 2005-03-09 |
CA2483464A1 (en) | 2003-11-27 |
AU2003231788B2 (en) | 2008-09-11 |
JP4545584B2 (ja) | 2010-09-15 |
CN1652778A (zh) | 2005-08-10 |
US20040033965A1 (en) | 2004-02-19 |
US20050137144A1 (en) | 2005-06-23 |
US20080188476A1 (en) | 2008-08-07 |
RU2341259C2 (ru) | 2008-12-20 |
WO2003097046A1 (en) | 2003-11-27 |
US20050143322A1 (en) | 2005-06-30 |
EP1505967A4 (en) | 2007-09-05 |
US20060009514A1 (en) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2004131636A (ru) | Способ лечения ожирения | |
MA27908A1 (fr) | Agents therapeutiques utiles pour le traitement de la douleur | |
CA2377330A1 (en) | Combination therapy for effecting weight loss and treating obesity | |
RU2214398C2 (ru) | Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения | |
TNSN07145A1 (fr) | Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique | |
AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
EP2186792A8 (en) | 2-(a-hydroxypentyl) benzoate and its preparation and use | |
EP2311851A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
RU2003130058A (ru) | Комбинации, включающие антидиарейный агент и эпотилон или производные эпотилона | |
RU2009141187A (ru) | Серосодержащие соединения как ингибиторы ns3 серинпротеазы вируса гепатита с | |
JP2011504903A5 (ru) | ||
RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
MA28742B1 (fr) | Derives de pyrido-pyrimidine, leur preparation, leur application en therapeutique | |
JP2005526024A5 (ru) | ||
CA2838387A1 (en) | Use of metallocene compounds for cancer treatment | |
RU2003134629A (ru) | Соединения цефема | |
RU2008110644A (ru) | Применение производных глутаровой кислоты или их фармацевтически приемлемых солей в качестве противоаритмических средств | |
RU2004111359A (ru) | Комбинированные агенты для лечения глаукомы | |
RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
RU2007105750A (ru) | Средство для лечения или профилактики сахарного диабета, ожирения или артериосклероза | |
ATE374605T1 (de) | Transdermale verabreichung von (r)-3,3- diphenylpropylamin-monoestern | |
ES2168084B1 (es) | Combinacion de aminas y compuestos de vanadio (iv) (v) para el tratatamiento y/o la prevencion de la diabetes mellitus. | |
RU99118510A (ru) | Композиция для лечения или предупреждения рака простаты |